EGFR and lung cancer: After adjustment for statin use, age, sex, urbanization, income, DM, hypertension, stroke, CAD, COPD, smoking-related disorders, CT/RT, EGFR-TKI response, and regimens before EGFR-TKI therapy, an increased risk of death was observed in male patients with lung cancer (HR: 1.28, 95% CI: 1.21–1.35, p <0.001), DM (HR: 1.17, 95% CI: 1.10–1.24, p < 0.001), stroke (HR: 1.10, 95% CI: 1.03–1.17, p = 0.006), and RT (HR: 1.20, 95% CI: 1.06–1.36, p = 0.005).